Amicus Therapeutics - FOLD Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FOLD shares.
View FOLD analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12-month price targets for Amicus Therapeutics' shares. Their FOLD share price forecasts range from $14.00 to $16.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 13.9% from the stock's current price.
View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts.

Amicus Therapeutics' stock was trading at $12.21 at the beginning of 2023. Since then, FOLD stock has increased by 7.9% and is now trading at $13.17.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our FOLD earnings forecast.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings data on Monday, November, 7th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.07. The biopharmaceutical company earned $81.69 million during the quarter, compared to analysts' expectations of $84.55 million. Amicus Therapeutics had a negative net margin of 81.65% and a negative trailing twelve-month return on equity of 123.94%.

Amicus Therapeutics issued an update on its FY 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $329.00 million-$329.00 million, compared to the consensus revenue estimate of $326.68 million.

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Amicus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.25%), Wedge Capital Management L L P NC (0.08%), Comerica Bank (0.03%), DNB Asset Management AS (0.01%), Fulton Bank N.A. (0.00%) and Park Avenue Securities LLC (0.00%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends.

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FOLD stock can currently be purchased for approximately $13.17.

Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.70 billion and generates $305.51 million in revenue each year. The biopharmaceutical company earns $-250,460,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

The company employs 496 workers across the globe.

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001.